These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1717223)

  • 1. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
    Murdoch D; McTavish D
    Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
    Merki HS; Bender W; Labs R
    J Clin Gastroenterol; 1989; 11 Suppl 1():S20-3; discussion S24. PubMed ID: 2572621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan.
    Inoue M
    Drugs; 1988; 35 Suppl 3():114-9. PubMed ID: 2905239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of roxatidine acetate: a review.
    Dammann HG; de Looze SM; Bender W; Labs R
    Scand J Gastroenterol Suppl; 1988; 146():121-34. PubMed ID: 2906456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
    Collins JD
    Scand J Gastroenterol Suppl; 1988; 146():89-99. PubMed ID: 2906472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
    Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
    Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD; Grant SM; Goa KL
    Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of roxatidine acetate in patients with chronic liver disease.
    Tsutsumi M; Ueshima Y; Takase S
    J Gastroenterol Hepatol; 2001 Aug; 16(8):910-5. PubMed ID: 11555106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New H2-receptor antagonist--roxatidine acetate--in treatment of duodenal ulcer.
    Amarapurkar DN; Parikh SS; Desai HG
    J Assoc Physicians India; 1993 Aug; 41(8):496-7. PubMed ID: 7904993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of roxatidine acetate in fasting patients prior to induction of anaesthesia as prophylaxis against the acid aspiration syndrome.
    Tryba M; Wruck G; Thole H; Zenz M
    Drugs; 1988; 35 Suppl 3():20-4. PubMed ID: 2905245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.
    Yasutake K; Amano M; Mizokami Y; Kubota S; Fukumoto H; Imamura Y; Yokoya H; Irie K
    J Int Med Res; 1998; 26(1):25-36. PubMed ID: 9513074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of roxatidine acetate and ranitidine in duodenal ulcer healing.
    Hüttemann W
    Drugs; 1988; 35 Suppl 3():90-5. PubMed ID: 2905255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Price AH; Brogden RN
    Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the animal pharmacology of roxatidine acetate.
    Scholtholt J; Bickel M; Herling AW
    Drugs; 1988; 35 Suppl 3():30-40. PubMed ID: 2905247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a new histamine H2-receptor antagonist, Z-300, on gastric secretion and gastro-duodenal lesions in rats: comparison with roxatidine.
    Okabe S; Takagi K; Igata H; Kato S; Shimosako K; Yamaji Y; Seiki M
    Jpn J Pharmacol; 1992 Jul; 59(3):275-89. PubMed ID: 1359178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxatidine acetate as maintenance treatment for patients with peptic ulcer disease. The European Cooperative Roxatidine Study Group.
    Clin Ther; 1991; 13(1):47-57. PubMed ID: 1674231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical and biologic characteristics of roxatidine acetate.
    Bickel M; Herling AW; Schoelkens B; Scholtholt J
    Scand J Gastroenterol Suppl; 1988; 146():78-88. PubMed ID: 2906471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of the histamine H2 receptor antagonist roxatidine acetate on stomach and liver alcohol dehydrogenase and serum alcohol level].
    Beil W; Sewing KF
    Z Gastroenterol; 1993 Nov; 31(11):643-5. PubMed ID: 7904786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.